Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 16.3% during mid-day trading on Thursday . The stock traded as high as C$0.28 and last traded at C$0.25. Approximately 610,571 shares changed hands during mid-day trading, a decline of 2% from the average daily volume of 621,060 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Performance
The stock has a market cap of C$23.52 million, a P/E ratio of -13.50 and a beta of 0.20. The firm has a 50-day moving average price of C$0.10 and a 200-day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Trading Stocks: RSI and Why it’s Useful
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- The How and Why of Investing in Gold Stocks
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
